Evidence map›Paper›PMID 37790614›Full record

ArticlePeerJ2023

Pathway2Targets: an open-source pathway-based approach to repurpose therapeutic drugs and prioritize human targets.

Mauri Dobbs Spendlove, Trenton M Gibson, Shaney McCain, Benjamin C Stone, Tristan Gill, Brett E Pickett

Abstract read
In one paragraph

Article in PeerJ, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Mauri Dobbs SpendloveMicrobiology and Molecular Biology, Brigham Young University, Provo, UT, United States of America.
Trenton M GibsonMicrobiology and Molecular Biology, Brigham Young University, Provo, UT, United States of America.
Shaney McCainMicrobiology and Molecular Biology, Brigham Young University, Provo, UT, United States of America.
Benjamin C StoneMicrobiology and Molecular Biology, Brigham Young University, Provo, UT, United States of America.
Tristan GillCarlsbad, California, United States.
Brett E PickettMicrobiology and Molecular Biology, Brigham Young University, Provo, UT, United States of America.ORCID 0000-0001-7930-8160

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Recent efforts to repurpose existing drugs to different indications have been accompanied by a number of computational methods, which incorporate protein-protein interaction networks and signaling pathways, to aid with prioritizing existing targets and/or drugs. However, many of these existing methods are focused on integrating additional data that are only available for a small subset of diseases or conditions. Methods: We have designed and implemented a new R-based open-source target prioritization and repurposing method that integrates both canonical intracellular signaling information from five public pathway databases and target information from public sources including OpenTargets.org. The Pathway2Targets algorithm takes a list of significant pathways as input, then retrieves and integrates public data for all targets within those pathways for a given condition. It also incorporates a weighting scheme that is customizable by the user to support a variety of use cases including target prioritization, drug repurposing, and identifying novel targets that are biologically relevant for a different indication. Results: As a proof of concept, we applied this algorithm to a public colorectal cancer RNA-sequencing dataset with 144 case and control samples. Our analysis identified 430 targets and ~700 unique drugs based on differential gene expression and signaling pathway enrichment. We found that our highest-ranked predicted targets were significantly enriched in targets with FDA-approved therapeutics for colorectal cancer (

Indexed as

Colorectal NeoplasmsQuality of LifeErbB ReceptorsHumansSignal TransductionErbB ReceptorsBioinformaticsColorectal cancerDrug repurposingDrug targetsPathwaysPredictionTargetTarget prioritization

Identifiers

PMID37790614
PMCPMC10544355

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.